Publication Date:
2020-11-05
Description:
Background:As the treatment options for ITP continue to expand, identifying which patients to treat with rituximab has become more complex. Recent guidelines for treatment with rituximab differ for ITP in adults as compared with children; thus, the decision to treat with rituximab may vary by age group. Objective:To describe the demographic and clinical characteristics of adult and pediatric patients with ITP treated with rituximab over the last 10 years. Methods:A retrospective review identified 64 patients with ITP who received rituximab at two tertiary academic medical centers. Eligibility included diagnosis of ITP and treatment with rituximab for ITP between January 2010 and December 2019. Demographic and clinical characteristics, laboratory studies, and treatments were collected. Rituximab response was defined as a platelet count ≥100 x 109/L within 6 months after first rituximab dose and the absence of treatment with steroids, intravenous immunoglobulin (IVIG), or second-line therapies in those 6 months. Results:The demographic and clinical characteristics of the cohort are described in the Table. In this cohort, 38% (24/64) of patients were
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink